Abstract
Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.
Keywords:
Apoptosis; Bcl-2; Hollow gold nanoshells; NuBCP; Peptide delivery; Resistant cancer.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacology
-
Apoptosis / drug effects
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Drug Carriers / chemistry
-
Drug Carriers / pharmacology
-
Drug Delivery Systems*
-
Drug Liberation
-
Drug Resistance, Neoplasm / drug effects
-
Gold / chemistry*
-
Humans
-
Laser Therapy
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy
-
Nanoshells / chemistry*
-
Oligopeptides / chemistry
-
Oligopeptides / pharmacology
-
Paclitaxel / pharmacology
-
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
-
Proto-Oncogene Proteins c-bcl-2 / metabolism*
-
Xenograft Model Antitumor Assays
-
Zebrafish / growth & development
-
Zebrafish / physiology
Substances
-
Antineoplastic Agents
-
BCL2 protein, human
-
Drug Carriers
-
Oligopeptides
-
Proto-Oncogene Proteins c-bcl-2
-
phenylalanyl-seryl-arginyl-seryl-leucyl-histidyl-seryl-leucyl-leucine
-
Gold
-
Paclitaxel